Literature DB >> 29886487

Transition of Care from Childhood to Adulthood: Congenital Adrenal Hyperplasia.

Anne Bachelot.   

Abstract

Deficiency of the 21-hydroxylase enzyme is the most common form of congenital adrenal hyperplasia (CAH), accounting for more than 95% of the cases. With the advent of newborn screening and hormone replacement therapy, most children with CAH survive into adulthood. Adolescents and adults with CAH experience a number of complications, including short stature, obesity, infertility, impaired bone mineral density, and reduced quality of life. Transition from pediatric to adult care and management of long-term complications are challenging for both patients and practitioners. In adulthood, the aims of the medical treatment are to substitute cortisol and, when necessary, aldosterone deficiency, to ensure normal fertility, and to avoid the long-term consequences of glucocorticoid use on bone, metabolism, and cardiovascular risk. Recent data suggest that poor health status is likely to begin in adolescence and persist into adulthood, highlighting the importance of this time period in a patient's endocrine care. During transition from pediatric to adult specific care, a shift in treatment goals is thus needed. Successful transition from pediatric to adult health care requires a regular follow-up of patients by a multidisciplinary team including pediatric endocrinologists, urologists, gynecologists, psychiatrists, and adult endocrinologists. All of this could be included in a specific therapeutic education program regarding transition and/or CAH.
© 2018 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29886487     DOI: 10.1159/000487523

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  6 in total

1.  In Reply.

Authors:  Uta Nennstiel
Journal:  Dtsch Arztebl Int       Date:  2021-07-12       Impact factor: 5.594

2.  Mapping Child and Adolescent Mental Health Services and the Interface During Transition to Adult Services in Six Swiss Cantons.

Authors:  Deniz Kilicel; Franco De Crescenzo; Remy Barbe; Anne Edan; Logos Curtis; Swaran Singh; Nadia Micali; Jean-Michel Aubry; Jacqueline Mégevand; Stephan Eliez; Kerstin Jessica Plessen; Marco Armando
Journal:  Front Psychiatry       Date:  2022-05-09       Impact factor: 5.435

3.  Care of the adolescent patient with congenital adrenal hyperplasia: Special considerations, shared decision making, and transition.

Authors:  Reeti Chawla; Meilan Rutter; Janet Green; Erica M Weidler
Journal:  Semin Pediatr Surg       Date:  2019-09-20       Impact factor: 2.754

Review 4.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 5.  Clinical outcomes and characteristics of P30L mutations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mirjana Kocova; Violeta Anastasovska; Henrik Falhammar
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

Review 6.  Novel treatments for congenital adrenal hyperplasia.

Authors:  Mariska A M Schröder; Hedi L Claahsen-van der Grinten
Journal:  Rev Endocr Metab Disord       Date:  2022-02-23       Impact factor: 9.306

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.